Galectin Therapeutics Inc Unit Cons of 2 shs + 1 Wt
(NASDAQ : GALTU)

( )
GALTU PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Loading GALTU News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
1.30%83.341.8%$745.39m
BIIBBiogen Inc.
1.17%241.711.0%$581.03m
CELGCelgene Corporation
-0.30%98.511.2%$467.26m
AMGNAmgen Inc.
1.37%152.151.0%$450.08m
REGNRegeneron Pharmaceuticals, Inc.
0.39%349.233.1%$325.50m
ALXNAlexion Pharmaceuticals, Inc.
2.27%116.762.5%$311.51m
ILMNIllumina, Inc.
1.97%140.294.9%$169.60m
TSROTESARO, Inc.
8.59%84.0515.8%$143.75m
VRTXVertex Pharmaceuticals Incorporated
1.20%86.022.6%$133.88m
MDVNMedivation, Inc.
-1.07%60.302.8%$132.96m
BMRNBioMarin Pharmaceutical Inc.
-0.73%77.804.0%$128.97m
AAgilent Technologies, Inc.
1.35%44.351.0%$104.36m
SRPTSarepta Therapeutics, Inc.
2.20%19.0749.4%$104.18m
EXASExact Sciences Corporation
8.50%12.2521.4%$102.22m
ACADACADIA Pharmaceuticals Inc.
0.25%32.4619.6%$95.68m

Company Profile

Galectin Therapeutics, Inc. operates as a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease and cancer. Its drug candidates are based on the method of targeting galectin proteins, which are key mediators of biologic and pathologic function and its focus is on diseases with serious, life-threatening consequences to patients and those where current treatment options are limited. The company was founded by James C. Czirr and Anatole A. Kltyosov on July 10, 2000 and is headquartered in Norcross, GA.